Farshid Dayyani

Title(s)Clinical Professor, Medicine
SchoolSchool of Medicine
Address1001 Health Sciences Road
Irvine CA 92697-3950
Phone(714) 456-5153
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Characterization of patients requiring inpatient hospital ethics consults- A single center study. PLoS One. 2024; 19(4):e0296763. Mahadevan A, Azizi A, Dastur C, Stern-Nezer S, Nahmias J, Dayyani F. PMID: 38564582; PMCID: PMC10986956.
      View in: PubMed   Mentions:    Fields:    
    2. A new biomarker panel for differential diagnosis of cholangiocarcinoma: Results from an exploratory analysis. Int J Biol Markers. 2024 Mar 28; 3936155241235185. Köhler B, Bes M, Chan HL, Esteban JI, Piratvisuth T, Sukeepaisarnjaroen W, Tanwandee T, Thongsawat S, Mang A, Morgenstern D, Swiatek-de Lange M, Dayyani F. PMID: 38549363.
      View in: PubMed   Mentions:    Fields:    
    3. Regional Therapy Approaches for Gastric Cancer with Limited Peritoneal Disease. J Gastrointest Cancer. 2024 Jan 26. Li AY, Sedighim S, Tajik F, Khan AM, Radhakrishnan VK, Dayyani F, Senthil M. PMID: 38277055.
      View in: PubMed   Mentions:    Fields:    
    4. Taxane-Based Chemotherapy Is Effective in Metastatic Appendiceal Adenocarcinoma. Oncologist. 2023 Dec 11; 28(12):e1303-e1305. Dansby J, More A, Zeineddine M, Yousef A, Bent A, Dayyani F, Wolff R, Overman M, Shen JP. PMID: 37738316; PMCID: PMC10712908.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    5. Novel combination approaches to locoregional and systemic therapy in the management of primary and metastatic liver tumors. Clin Adv Hematol Oncol. 2023 Dec; 21(12):633-643. Dai M, Tiu BY, Chen M, Sing C, Sharma V, Hoyos JP, Scherr R, Lin WJ, Breuer JA, Dayyani F, Imagawa D, Abi-Jaoudeh N. PMID: 38039057.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    6. A Phase 1 Study of Cabozantinib and Trifluridine/Tipiracil in Metastatic Colorectal Adenocarcinoma. Clin Colorectal Cancer. 2024 03; 23(1):67-72. Dayyani F, Balangue J, Valerin J, Keating MJ, Zell JA, Taylor TH, Cho MT. PMID: 38103947.
      View in: PubMed   Mentions:    Fields:    Translation:CTClinical Trials
    7. Progenitor-like exhausted SPRY1+CD8+ T cells potentiate responsiveness to neoadjuvant PD-1 blockade in esophageal squamous cell carcinoma. Cancer Cell. 2023 11 13; 41(11):1852-1870.e9. Liu Z, Zhang Y, Ma N, Yang Y, Ma Y, Wang F, Wang Y, Wei J, Chen H, Tartarone A, Velotta JB, Dayyani F, Gabriel E, Wakefield CJ, Kidane B, Carbonelli C, Long L, Liu Z, Su J, Li Z. PMID: 37832554.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    8. Role of Iterative Normothermic Intraperitoneal Paclitaxel Combined with Systemic Chemotherapy in the Management of Gastric Peritoneal Carcinomatosis. Ann Surg Oncol. 2024 02; 31(2):694-696. Senthil M, Dayyani F. PMID: 37684365.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    9. Partial Reversal of Anosmia Following Platinum-Based Chemotherapy in a Patient With Colorectal Adenocarcinoma. Cureus. 2023 Sep; 15(9):e44727. Mahadevan A, Azizi A, Bhandarkar N, Dayyani F. PMID: 37674764; PMCID: PMC10479930.
      View in: PubMed   Mentions:
    10. Taxane-based Chemotherapy is Effective in Metastatic Appendiceal Adenocarcinoma. medRxiv. 2023 Jul 13. Dansby J, More A, Zeineddine M, Yousef A, Bent A, Dayyani F, Wolff R, Overman M, Shen JP. PMID: 37502847; PMCID: PMC10370227.
      View in: PubMed   Mentions:
    11. Endometrial Adenocarcinoma with Discordant Microsatellite Stability Status Treated with First-Line Pembrolizumab: A Case Report and Narrative Review. Am J Case Rep. 2023 Jun 29; 24:e939448. Grant CR, Chiao EJ, Arter ZL, Johnson C, Tran T, Dayyani F, Tewari K, Vilchez V, Carmichael J, Cho M. PMID: 37381599; PMCID: PMC10316721.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    12. Targeting Hypoxia-Inducible Factor-1α for the Management of Hepatocellular Carcinoma. Cancers (Basel). 2023 May 12; 15(10). Huynh KN, Rao S, Roth B, Bryan T, Fernando DM, Dayyani F, Imagawa D, Abi-Jaoudeh N. PMID: 37345074; PMCID: PMC10216171.
      View in: PubMed   Mentions: 5  
    13. Durable Response after Repeat Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in a Patient with Extensive Mucinous Adenocarcinoma of the Appendix. Diseases. 2023 Apr 06; 11(2). Kaakour D, Ward G, Senthil M, Dayyani F. PMID: 37092442; PMCID: PMC10123748.
      View in: PubMed   Mentions: 1  
    14. A multicenter, phase Ib/II, open-label study of tivozanib with durvalumab in advanced hepatocellular carcinoma (DEDUCTIVE). Future Oncol. 2022 Dec; 18(40):4465-4471. Mahmood S, Li D, Lee A, Rowe J, Beg M, Kasturi V, Iyer R, Abrams T, Dayyani F. PMID: 36912078.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    15. Medullary carcinoma of the duodenum treated with pembrolizumab: a case report. J Gastrointest Oncol. 2023 Apr 29; 14(2):1149-1154. Liu L, Kaur S, Dayyani F, Cho M, Ran-Castillo D, Chong E, Khandelwal K, Demisse R. PMID: 37201040; PMCID: PMC10186505.
      View in: PubMed   Mentions:
    16. Phase II clinical trial of sequential treatment with systemic chemotherapy and intraperitoneal paclitaxel for gastric and gastroesophageal junction peritoneal carcinomatosis - STOPGAP trial. BMC Cancer. 2023 Mar 04; 23(1):209. Senthil M, Dayyani F. PMID: 36870941; PMCID: PMC9985848.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    17. Exosomes as a Source of Biomarkers for Gastrointestinal Cancers. Cancers (Basel). 2023 Feb 16; 15(4). Yu J, Ostowari A, Gonda A, Mashayekhi K, Dayyani F, Hughes CCW, Senthil M. PMID: 36831603; PMCID: PMC9954462.
      View in: PubMed   Mentions: 3  
    18. Expanding access to early phase trials: the CATCH-UP.2020 experience. JNCI Cancer Spectr. 2023 01 03; 7(1). Baranda JC, Diaz FJ, Rubinstein L, Shields AF, Dayyani F, Mehta A, Mehnert JM, Trent J, Mabaera R, Mooney M, Moscow JA, Doroshow J, Waters B, Ivy P, Gore SD, Thomas A. PMID: 36525371; PMCID: PMC9825762.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    19. Rapid and Deep Response to Lorlatinib in Pancreatic High-Grade Neuroendocrine Carcinoma With a Treatment Emergent Novel KANK1-ALK Fusion. JCO Precis Oncol. 2023 01; 7:e2200230. Dayyani F, Lee W, Houshyar R, Fontaine P. PMID: 36623237.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    20. Second-line treatment options for patients with metastatic pancreatic ductal adenocarcinoma: A systematic literature review. Cancer Treat Rev. 2023 Feb; 113:102502. Dayyani F, Macarulla T, Johnson A, Wainberg ZA. PMID: 36641880.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    21. Analysis of Circulating Tumor DNA to Predict Risk of Recurrence in Patients With Esophageal and Gastric Cancers. JCO Precis Oncol. 2022 12; 6:e2200420. Huffman BM, Aushev VN, Budde GL, Chao J, Dayyani F, Hanna D, Botta GP, Catenacci DVT, Maron SB, Krinshpun S, Sharma S, George GV, Malhotra M, Jurdi A, Moshkevich S, Aleshin A, Kasi PM, Klempner SJ. PMID: 36480779; PMCID: PMC10530958.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    22. The role of cytoreductive surgery and intraperitoneal chemotherapy in gastric cancer. Clin Adv Hematol Oncol. 2022 Nov; 20(11):673-682. Young S, Ostowari A, Yu J, Eng OS, Dayyani F, Senthil M. PMID: 36331405.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    23. Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma. J Immunother Cancer. 2022 10; 10(10). Brown LC, Zhu J, Desai K, Kinsey E, Kao C, Lee YH, Pabla S, Labriola MK, Tran J, Dragnev KH, Tafe LJ, Dayyani F, Gupta RT, McCall S, George DJ, Glenn ST, Nesline MK, George S, Zibelman M, Morrison C, Ornstein MC, Zhang T. PMID: 36252996; PMCID: PMC9577926.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    24. ASO Author Reflections: Challenges of Circulating Tumor DNA in the Management of Gastrointestinal Peritoneal Carcinomatosis. Ann Surg Oncol. 2022 Sep 13. Sullivan BG, Dayyani F, Senthil M. PMID: 36100836.
      View in: PubMed   Mentions:    Fields:    
    25. Analysis of delay in adjuvant chemotherapy in locally advanced rectal cancer. Tech Coloproctol. 2022 Aug 30. Farzaneh CA, Pigazzi A, Duong WQ, Carmichael JC, Stamos MJ, Dekhordi-Vakil F, Dayyani F, Zell JA, Jafari MD. PMID: 36042105.
      View in: PubMed   Mentions: 1     Fields:    
    26. Circulating Tumor DNA is Unreliable to Detect Somatic Gene Alterations in Gastrointestinal Peritoneal Carcinomatosis. Ann Surg Oncol. 2022 Aug 18. Sullivan BG, Lo A, Yu J, Gonda A, Dehkordi-Vakil F, Dayyani F, Senthil M. PMID: 35980549.
      View in: PubMed   Mentions: 11     Fields:    
    27. Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma. Clin Cancer Res. 2022 08 15; 28(16):3537-3545. Zhu AX, Dayyani F, Yen CJ, Ren Z, Bai Y, Meng Z, Pan H, Dillon P, Mhatre SK, Gaillard VE, Hernandez S, Kelley RK, Sangro B. PMID: 35435967.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCTClinical Trials
    28. Prevalence of Primary Liver Cancer is Affected by Place of Birth in Hispanic People Residing in the United States: All of Us Research Program Report. Am Surg. 2022 Oct; 88(10):2565-2571. Yu J, Sullivan BG, Senthil GN, Gonda A, Dehkordi-Vakil F, Campos B, Dayyani F, Senthil M. PMID: 35854430.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    29. Spontaneous Fluctuations of Tumor-Informed Circulating Tumor DNA at Low Levels. JCO Precis Oncol. 2022 07; 6:e2200177. Dayyani F, Senthil M. PMID: 35834756.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    30. Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. Nat Med. 2022 08; 28(8):1599-1611. Zhu AX, Abbas AR, de Galarreta MR, Guan Y, Lu S, Koeppen H, Zhang W, Hsu CH, He AR, Ryoo BY, Yau T, Kaseb AO, Burgoyne AM, Dayyani F, Spahn J, Verret W, Finn RS, Toh HC, Lujambio A, Wang Y. PMID: 35739268.
      View in: PubMed   Mentions: 114     Fields:    Translation:Humans
    31. A phase Ib feasibility trial of response adapted neoadjuvant therapy in gastric cancer (RANT-GC). Future Oncol. 2022 Jul; 18(21):2615-2622. Dayyani F, Smith BR, Nguyen NT, Daly S, Hinojosa MW, Seyedin SN, Kuo J, Samarasena JB, Lee JG, Taylor TH, Cho MT, Senthil M. PMID: 35603628; PMCID: PMC9437768.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    32. A phase 1b multicenter study of TAS-102 in combination with irinotecan in patients with advanced recurrent or unresectable gastric and gastroesophageal adenocarcinoma after at least one line of treatment with a fluoropyrimidine and platinum-containing regimen. Med Oncol. 2022 May 23; 39(5):102. Dayyani F, Tam K, Kim EJ, Ejadi S, Valerin J, Taylor TH, Cho MT. PMID: 35599264; PMCID: PMC9769492.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    33. BRCA-Mutated Pancreatic Cancer: From Discovery to Novel Treatment Paradigms. Cancers (Basel). 2022 May 16; 14(10). Devico Marciano N, Kroening G, Dayyani F, Zell JA, Lee FC, Cho M, Valerin JG. PMID: 35626055; PMCID: PMC9140002.
      View in: PubMed   Mentions: 5  
    34. Early Adoption of Checkpoint Inhibitors in Patients with Metastatic Gastric Adenocarcinoma-A Case Series of Non-Operative Long-Term Survivors. Diseases. 2022 Apr 24; 10(2). Kaakour D, Ward G, Dayyani F. PMID: 35645245; PMCID: PMC9149843.
      View in: PubMed   Mentions:
    35. Optimizing the Diagnosis and Biomarker Testing for Patients with Intrahepatic Cholangiocarcinoma: A Multidisciplinary Approach. Cancers (Basel). 2022 Jan 13; 14(2). Cho MT, Gholami S, Gui D, Tejaswi SL, Fananapazir G, Abi-Jaoudeh N, Jutric Z, Samarasena JB, Li X, Valerin JB, Mercer J, Dayyani F. PMID: 35053557; PMCID: PMC8773504.
      View in: PubMed   Mentions: 3  
    36. Screening and verification of potential gene targets in esophageal carcinoma by bioinformatics analysis and immunohistochemistry. Ann Transl Med. 2022 Jan; 10(2):70. Wen P, Dayyani F, Tao R, Zhong X. PMID: 35282073; PMCID: PMC8848373.
      View in: PubMed   Mentions: 1  
    37. Utility of tumor-informed circulating tumor DNA in the clinical management of gastrointestinal malignancies. J Gastrointest Oncol. 2021 Dec; 12(6):2643-2652. Zhang S, Brazel D, Kumar P, Schafer LN, Eidenschink B, Senthil M, Dayyani F. PMID: 35070394; PMCID: PMC8748058.
      View in: PubMed   Mentions: 5  
    38. Immediate Adjuvant Chemotherapy in Non-Metastatic Colon Cancer: Phase I Trial Evaluating a Novel Treatment Protocol. Clin Colorectal Cancer. 2022 06; 21(2):114-121. Jafari MD, Carmichael JC, Dayyani F, McKinney C, Wenzel L, Zell JA, Pigazzi A. PMID: 34980534.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    39. Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure-safety analyses in patients with metastatic pancreatic cancer. CPT Pharmacometrics Syst Pharmacol. 2021 12; 10(12):1550-1563. Brendel K, Bekaii-Saab T, Boland PM, Dayyani F, Dean A, Macarulla T, Maxwell F, Mody K, Pedret-Dunn A, Wainberg ZA, Zhang B. PMID: 34750990; PMCID: PMC8674005.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    40. Hyperprogression in Gastric Cancer: Is MDM2 Amplification the Dark Horse? JCO Precis Oncol. 2021 11; 5:931-932. Dayyani F, Kato S, Kurzrock R. PMID: 34994620.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    41. Phase I Trial on Arterial Embolization with Hypoxia Activated Tirapazamine for Unresectable Hepatocellular Carcinoma. J Hepatocell Carcinoma. 2021; 8:421-434. Abi-Jaoudeh N, Dayyani F, Chen PJ, Fernando D, Fidelman N, Javan H, Liang PC, Hwang JI, Imagawa DK. PMID: 34041204; PMCID: PMC8139681.
      View in: PubMed   Mentions: 10  Translation:CTClinical Trials
    42. First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study. Eur J Cancer. 2021 07; 151:14-24. Wainberg ZA, Bekaii-Saab T, Boland PM, Dayyani F, Macarulla T, Mody K, Belanger B, Maxwell F, Moore Y, Thiagalingam A, Wang T, Zhang B, Dean A. PMID: 33957442.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    43. Immunotherapy Updates in Advanced Hepatocellular Carcinoma. Cancers (Basel). 2021 Apr 30; 13(9). Singh A, Beechinor RJ, Huynh JC, Li D, Dayyani F, Valerin JB, Hendifar A, Gong J, Cho M. PMID: 33946408; PMCID: PMC8125389.
      View in: PubMed   Mentions: 5  
    44. Therapy in Advanced Hepatocellular Carcinoma. Semin Intervent Radiol. 2020 Dec; 37(5):466-474. Javan H, Dayyani F, Abi-Jaoudeh N. PMID: 33328702; PMCID: PMC7732574.
      View in: PubMed   Mentions: 10  
    45. Variability in multimodality treatment influences survival in non-metastatic gastric cancer patients. J Gastrointest Oncol. 2020 Oct; 11(5):952-963. Hoang T, Dayyani F, Alfaro A, Huynh J, Ji J, Ko AH, Cho M, Hiyama D. PMID: 33209490; PMCID: PMC7657833.
      View in: PubMed   Mentions:
    46. Peritoneal carcinomatosis in gastric cancer: Are Hispanics at higher risk? J Surg Oncol. 2020 Dec; 122(8):1624-1629. Choi AH, Ji L, Babcock B, Ramos V, Kwong MLM, Morgan JW, Selleck MJ, Langridge WHR, DeLeon M, Wall NR, Lum S, Pigazzi A, Dayyani F, Senthil M. PMID: 32901938.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    47. A continuous responder algorithm to optimize clinical management of small-cell lung cancer with progastrin-releasing peptide as a simple blood test. Tumour Biol. 2020 Sep; 42(9):1010428320958603. Muley T, Zhang X, Holdenrieder S, Korse CM, Zhi XY, Molina R, Liu Z, Hartmann G, van den Heuvel MM, Qian K, Marrades R, Engel C, He Y, Wehnl B, Dayyani F, Herth F. PMID: 32964798.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    48. Neoadjuvant Immunotherapy-Based Systemic Treatment in MMR-Deficient or MSI-High Rectal Cancer: Case Series. J Natl Compr Canc Netw. 2020 07; 18(7):798-804. Demisse R, Damle N, Kim E, Gong J, Fakih M, Eng C, Oesterich L, McKenny M, Ji J, Liu J, Louie R, Tam K, Gholami S, Halabi W, Monjazeb A, Dayyani F, Cho M. PMID: 32634770.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    49. Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients. Oncoimmunology. 2020 06 10; 9(1):1773200. Zhang T, Pabla S, Lenzo FL, Conroy JM, Nesline MK, Glenn ST, Papanicolau-Sengos A, Burgher B, Giamo V, Andreas J, Wang Y, Bshara W, Madden KG, Shirai K, Dragnev K, Tafe LJ, Gupta R, Zhu J, Labriola M, McCall S, George DJ, Ghatalia P, Dayyani F, Edwards R, Park MS, Singh R, Jacob R, George S, Xu B, Zibelman M, Kurzrock R, Morrison C. PMID: 32923131; PMCID: PMC7458647.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    50. Predictors of outcomes in patients with gastric cancer treated with contemporary multimodality strategies-a single institution experience. J Gastrointest Oncol. 2020 Apr; 11(2):411-420. Hoang T, Park M, Hiyama D, Dayyani F. PMID: 32399281; PMCID: PMC7212096.
      View in: PubMed   Mentions: 1  
    51. Gene mutations distinguishing gastric from colorectal and esophageal adenocarcinomas. J Gastrointest Oncol. 2020 Feb; 11(1):45-54. Hoang T, Ganesan AK, Hiyama D, Dayyani F. PMID: 32175104; PMCID: PMC7052769.
      View in: PubMed   Mentions: 1  
    52. Management of Urothelial Bladder Cancer in Clinical Practice: Real-World Answers to Difficult Questions. J Oncol Pract. 2019 08; 15(8):421-428. Mar N, Dayyani F. PMID: 31404517.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    53. FGFR2-Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic Landscape. Oncologist. 2019 11; 24(11):1462-1468. Klempner SJ, Madison R, Pujara V, Ross JS, Miller VA, Ali SM, Schrock AB, Kim ST, Maron SB, Dayyani F, Catenacci DVT, Lee J, Chao J. PMID: 31249137; PMCID: PMC6853122.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    54. Potential for the blood-based biomarkers cytokeratin 19 fragment (CYFRA 21-1) and human epididymal protein 4 (HE4) to detect recurrence during monitoring after surgical resection of adenocarcinoma of the lung. Lung Cancer. 2019 04; 130:194-200. Muley T, He Y, Rolny V, Wehnl B, Escherich A, Warth A, Stolp C, Schneider MA, Meister M, Herth FJ, Dayyani F. PMID: 30885344.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    55. Analysis of MDM2 Amplification: Next-Generation Sequencing of Patients With Diverse Malignancies. JCO Precis Oncol. 2018; 2018. Kato S, Ross JS, Gay L, Dayyani F, Roszik J, Subbiah V, Kurzrock R. PMID: 30148248; PMCID: PMC6106866.
      View in: PubMed   Mentions: 32     Fields:    
    56. Technical and clinical performance of a new assay to detect squamous cell carcinoma antigen levels for the differential diagnosis of cervical, lung, and head and neck cancer. Tumour Biol. 2018 Apr; 40(4):1010428318772202. Holdenrieder S, Molina R, Qiu L, Zhi X, Rutz S, Engel C, Kasper-Sauer P, Dayyani F, Korse CM. PMID: 29701125.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    57. The combination of the blood based tumor biomarkers cytokeratin 19 fragments (CYFRA 21-1) and carcinoembryonic antigen (CEA) as a potential predictor of benefit from adjuvant chemotherapy in early stage squamous cell carcinoma of the lung (SCC). Lung Cancer. 2018 06; 120:46-53. Muley T, Rolny V, He Y, Wehnl B, Escherich A, Warth A, Stolp C, Schneider MA, Dienemann H, Meister M, Herth FJ, Dayyani F. PMID: 29748014.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    58. Carcinoembryonic antigen and cytokeratin-19 fragments for assessment of therapy response in non-small cell lung cancer: a systematic review and meta-analysis. Br J Cancer. 2017 Apr 11; 116(8):1037-1045. Holdenrieder S, Wehnl B, Hettwer K, Simon K, Uhlig S, Dayyani F. PMID: 28278517; PMCID: PMC5396105.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    59. Letter in response to: Identifying risk in the use of tumor markers to improve patient safety. Clin Chem Lab Med. 2016 12 01; 54(12):e383-e384. Dayyani F, Morgenstern D. PMID: 27467754.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    60. Clinically Meaningful Use of Blood Tumor Markers in Oncology. Biomed Res Int. 2016; 2016:9795269. Holdenrieder S, Pagliaro L, Morgenstern D, Dayyani F. PMID: 28042579; PMCID: PMC5155072.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    61. Diagnostic Performance of Risk of Ovarian Malignancy Algorithm Against CA125 and HE4 in Connection With Ovarian Cancer: A Meta-analysis. Int J Gynecol Cancer. 2016 11; 26(9):1586-1593. Dayyani F, Uhlig S, Colson B, Simon K, Rolny V, Morgenstern D, Schlumbrecht M. PMID: 27540691.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    62. The combination of serum insulin, osteopontin, and hepatocyte growth factor predicts time to castration-resistant progression in androgen dependent metastatic prostate cancer- an exploratory study. BMC Cancer. 2016 09 06; 16:721. Dayyani F, Zurita AJ, Nogueras-González GM, Slack R, Millikan RE, Araujo JC, Gallick GE, Logothetis CJ, Corn PG. PMID: 27599544; PMCID: PMC5013640.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    63. TLE4 regulation of wnt-mediated inflammation underlies its role as a tumor suppressor in myeloid leukemia. Leuk Res. 2016 09; 48:46-56. Shin TH, Brynczka C, Dayyani F, Rivera MN, Sweetser DA. PMID: 27486062; PMCID: PMC5266616.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    64. In Response to "Serum Tumor Marker Use in Patients With Advanced Solid Tumors". J Oncol Pract. 2016 Mar; 12(3):273-4. Dayyani F, Morgenstern D, Holdenrieder S. PMID: 26837562.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    65. Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001). Cancer Chemother Pharmacol. 2014 Aug; 74(2):379-87. Dragovich T, Laheru D, Dayyani F, Bolejack V, Smith L, Seng J, Burris H, Rosen P, Hidalgo M, Ritch P, Baker AF, Raghunand N, Crowley J, Von Hoff DD. PMID: 24939212; PMCID: PMC4461053.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCTClinical Trials
    66. Management of advanced primary urethral carcinomas. BJU Int. 2014 Jul; 114(1):25-31. Dayyani F, Hoffman K, Eifel P, Guo C, Vikram R, Pagliaro LC, Pettaway C. PMID: 24447439.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    67. Ligand-independent activation of MET through IGF-1/IGF-1R signaling. Int J Cancer. 2013 Oct 01; 133(7):1536-46. Varkaris A, Gaur S, Parikh NU, Song JH, Dayyani F, Jin JK, Logothetis CJ, Gallick GE. PMID: 23526299; PMCID: PMC3713179.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansAnimalsCells
    68. Increased serum insulin-like growth factor-1 levels are associated with prolonged response to dasatinib-based regimens in metastatic prostate cancer. Prostate. 2013 Jun; 73(9):979-85. Dayyani F, Varkaris A, Araujo JC, Song JH, Chatterji T, Trudel GC, Logothetis CJ, Gallick GE. PMID: 23371521; PMCID: PMC4013833.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    69. Combined Inhibition of IGF-1R/IR and Src family kinases enhances antitumor effects in prostate cancer by decreasing activated survival pathways. PLoS One. 2012; 7(12):e51189. Dayyani F, Parikh NU, Varkaris AS, Song JH, Moorthy S, Chatterji T, Maity SN, Wolfe AR, Carboni JM, Gottardis MM, Logothetis CJ, Gallick GE. PMID: 23300537; PMCID: PMC3530555.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansAnimalsCells
    70. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin Cancer Res. 2013 Feb 01; 19(3):657-67. Mao M, Tian F, Mariadason JM, Tsao CC, Lemos R, Dayyani F, Gopal YN, Jiang ZQ, Wistuba II, Tang XM, Bornman WG, Bollag G, Mills GB, Powis G, Desai J, Gallick GE, Davies MA, Kopetz S. PMID: 23251002; PMCID: PMC3563727.
      View in: PubMed   Mentions: 150     Fields:    Translation:HumansAnimalsCells
    71. Plasmacytoid urothelial carcinoma, a chemosensitive cancer with poor prognosis, and peritoneal carcinomatosis. J Urol. 2013 May; 189(5):1656-61. Dayyani F, Czerniak BA, Sircar K, Munsell MF, Millikan RE, Dinney CP, Siefker-Radtke AO. PMID: 23159581; PMCID: PMC4243847.
      View in: PubMed   Mentions: 53     Fields:    Translation:Humans
    72. Retrospective analysis of survival outcomes and the role of cisplatin-based chemotherapy in patients with urethral carcinomas referred to medical oncologists. Urol Oncol. 2013 Oct; 31(7):1171-7. Dayyani F, Pettaway CA, Kamat AM, Munsell MF, Sircar K, Pagliaro LC. PMID: 22534087; PMCID: PMC4131852.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    73. Transcript profiling of CD16-positive monocytes reveals a unique molecular fingerprint. Eur J Immunol. 2012 Apr; 42(4):957-74. Frankenberger M, Hofer TP, Marei A, Dayyani F, Schewe S, Strasser C, Aldraihim A, Stanzel F, Lang R, Hoffmann R, Prazeres da Costa O, Buch T, Ziegler-Heitbrock L. PMID: 22531920.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansCellsCTClinical Trials
    74. The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials. Expert Opin Investig Drugs. 2011 Dec; 20(12):1677-84. Varkaris A, Corn PG, Gaur S, Dayyani F, Logothetis CJ, Gallick GE. PMID: 22035268; PMCID: PMC4020016.
      View in: PubMed   Mentions: 46     Fields:    Translation:Humans
    75. Novel therapies for metastatic castrate-resistant prostate cancer. J Natl Cancer Inst. 2011 Nov 16; 103(22):1665-75. Dayyani F, Gallick GE, Logothetis CJ, Corn PG. PMID: 21917607; PMCID: PMC4176261.
      View in: PubMed   Mentions: 53     Fields:    Translation:HumansAnimalsCells
    76. Prediction model for mortality after intracranial hemorrhage in patients with leukemia. Am J Hematol. 2011 Jul; 86(7):546-9. Dayyani F, Mougalian SS, Naqvi K, Shan J, Ravandi F, Cortes J, Weinberg J, Jabbour E, Faderl S, Wierda W, Thomas D, O'Brien S, Pierce S, Kantarjian H, Garcia-Manero G. PMID: 21509801; PMCID: PMC4712950.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    77. Steps in prostate cancer progression that lead to bone metastasis. Int J Cancer. 2011 Jun 01; 128(11):2545-61. Jin JK, Dayyani F, Gallick GE. PMID: 21365645; PMCID: PMC3082284.
      View in: PubMed   Mentions: 86     Fields:    Translation:HumansAnimals
    78. Outcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy. Cancer. 2011 Jan 01; 117(1):110-5. Dayyani F, Kantarjian H, O'Brien S, Pierce S, Jones D, Faderl S, Garcia-Manero G, Cortes J, Ravandi F. PMID: 20803607; PMCID: PMC4287232.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    79. Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC). Head Neck Oncol. 2010 Jun 29; 2:15. Dayyani F, Etzel CJ, Liu M, Ho CH, Lippman SM, Tsao AS. PMID: 20587061; PMCID: PMC2908081.
      View in: PubMed   Mentions: 201     Fields:    Translation:HumansCells
    80. Cause of death in patients with lower-risk myelodysplastic syndrome. Cancer. 2010 May 01; 116(9):2174-9. Dayyani F, Conley AP, Strom SS, Stevenson W, Cortes JE, Borthakur G, Faderl S, O'Brien S, Pierce S, Kantarjian H, Garcia-Manero G. PMID: 20162709; PMCID: PMC3753205.
      View in: PubMed   Mentions: 55     Fields:    Translation:Humans
    81. HIV-associated multicentric Castleman's disease. Am J Hematol. 2008 Jun; 83(6):498-503. Stebbing J, Pantanowitz L, Dayyani F, Sullivan RJ, Bower M, Dezube BJ. PMID: 18260115.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCells
    82. Mutations in the neutral sphingomyelinase gene SMPD3 implicate the ceramide pathway in human leukemias. Blood. 2008 May 01; 111(9):4716-22. Kim WJ, Okimoto RA, Purton LE, Goodwin M, Haserlat SM, Dayyani F, Sweetser DA, McClatchey AI, Bernard OA, Look AT, Bell DW, Scadden DT, Haber DA. PMID: 18299447; PMCID: PMC2343601.
      View in: PubMed   Mentions: 52     Fields:    Translation:HumansAnimalsCells
    83. Loss of TLE1 and TLE4 from the del(9q) commonly deleted region in AML cooperates with AML1-ETO to affect myeloid cell proliferation and survival. Blood. 2008 Apr 15; 111(8):4338-47. Dayyani F, Wang J, Yeh JR, Ahn EY, Tobey E, Zhang DE, Bernstein ID, Peterson RT, Sweetser DA. PMID: 18258796; PMCID: PMC2288729.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansAnimalsCells
    84. Multicentric Castleman's disease masquerading as HIV-related lymphoma. Am J Med Sci. 2007 Oct; 334(4):317-9. Dayyani F, Pantanowitz L, Sandridge TG, Sullivan RJ, Dezube BJ. PMID: 18030193.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    85. Delineation of the minimal commonly deleted segment and identification of candidate tumor-suppressor genes in del(9q) acute myeloid leukemia. Genes Chromosomes Cancer. 2005 Nov; 44(3):279-91. Sweetser DA, Peniket AJ, Haaland C, Blomberg AA, Zhang Y, Zaidi ST, Dayyani F, Zhao Z, Heerema NA, Boultwood J, Dewald GW, Paietta E, Slovak ML, Willman CL, Wainscoat JS, Bernstein ID, Daly SB. PMID: 16015647.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCells
    86. The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion-mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase. Blood. 2004 Sep 15; 104(6):1825-32. Schmidmaier R, Baumann P, Simsek M, Dayyani F, Emmerich B, Meinhardt G. PMID: 15161667.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansAnimalsCells
    87. Impact of type-I-interferon on monocyte subsets and their differentiation to dendritic cells. An in vivo and ex vivo study in multiple sclerosis patients treated with interferon-beta. J Neuroimmunol. 2004 Jan; 146(1-2):176-88. Then Bergh F, Dayyani F, Ziegler-Heitbrock L. PMID: 14698861.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    88. Autologous stem-cell transplantation restores the functional properties of CD14+CD16+ monocytes in patients with myeloma and lymphoma. J Leukoc Biol. 2004 Feb; 75(2):207-13. Dayyani F, Joeinig A, Ziegler-Heitbrock L, Schmidmaier R, Straka C, Emmerich B, Meinhardt G. PMID: 14576364.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    89. Treosulfan is an effective inducer of cell death in myeloma cell lines and primary myeloma cells from patients. Br J Haematol. 2003 Sep; 122(6):892-9. Meinhardt G, Dayyani F, Jahrsdörfer B, Baumgart J, Emmerich B, Schmidmaier R. PMID: 12956758.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    90. Mechanism of glucocorticoid-induced depletion of human CD14+CD16+ monocytes. J Leukoc Biol. 2003 Jul; 74(1):33-9. Dayyani F, Belge KU, Frankenberger M, Mack M, Berki T, Ziegler-Heitbrock L. PMID: 12832440.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansCells
    91. The proinflammatory CD14+CD16+DR++ monocytes are a major source of TNF. J Immunol. 2002 Apr 01; 168(7):3536-42. Belge KU, Dayyani F, Horelt A, Siedlar M, Frankenberger M, Frankenberger B, Espevik T, Ziegler-Heitbrock L. PMID: 11907116.
      View in: PubMed   Mentions: 330     Fields:    Translation:HumansCells
    92. Selective mobilization of CD14(+)CD16(+) monocytes by exercise. Am J Physiol Cell Physiol. 2000 Sep; 279(3):C578-86. Steppich B, Dayyani F, Gruber R, Lorenz R, Mack M, Ziegler-Heitbrock HW. PMID: 10942707.
      View in: PubMed   Mentions: 53     Fields:    Translation:HumansCells
    Farshid's Networks
    Concepts (389)
    Derived automatically from this person's publications.
    Co-Authors (43)
    People in Profiles who have published with this person.
    Similar People (60)
    People who share similar concepts with this person.
    Same Department
    Search Department